Researchers Outline How Radiopharmaceutical Therapies Are Transforming Systemic Precision Cancer Treatment

Radiopharmaceutical therapy has evolved from organ-seeking compounds and early antibody-based regimens into a sophisticated precision oncology discipline that integrates molecular imaging, target selection, targeted radionuclide therapy, absorbed-dose estimation, and coordinated multidisciplinary clinical care. In a comprehensive review published in Frontiers in Nuclear Medicine, researchers Vidhula Ahire and Yang-Hong Dai of the University of Oxford and Tri-Service General Hospital examine how systemic radiation delivery is shifting from an empirical intervention into a precision-guided cancer treatment. Unlike conventional external-beam radiotherapy, which directs ionizing beams through externally planned geometric pathways, therapeutic radiopharmaceuticals deliver radiation systemically or locoregionally to deposit energy based on target expression, physiological clearance, blood circulation, tissue uptake, and microscopic retention. Consequently, therapeutic efficacy and normal-organ toxicity are determined not solely by the quantity of administered radioactivity, but by organ biodistribution, dose rate, cellular residence time, and radiation biology. This fundamental operational shift requires cancer specialists to evaluate target biology, isotope physics, and delivery logistics as interconnected elements of an engineered treatment system.

The therapeutic armamentarium currently rests on several regulatory-grade agents established across distinct malignancies. Long-standing modalities include radioactive iodine for differentiated thyroid carcinoma, where physiological transport mechanisms support targeted remnant ablation and treatment of metastatic disease, alongside high-specific-activity iodine-131 metaiodobenzylguanidine for advanced, unresectable pheochromocytoma and paraganglioma. Modern systemic oncology has increasingly integrated targeted radioligands, most notably lutetium-177 dotatate for progressive somatostatin receptor-positive neuroendocrine tumors and lutetium-177 PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. Clinical practice also incorporates bone-seeking inorganic radium-223 dichloride for bone-predominant metastatic castration-resistant prostate cancer and locoregional yttrium-90 microsphere radioembolization for primary hepatocellular carcinoma and liver-dominant metastases. However, these established treatments consistently demonstrate that administering equal levels of radioactivity can yield widely differing absorbed radiation doses across patients and individual tumor deposits, highlighting the necessity of looking beyond fixed-activity protocols.

Peptide receptor radionuclide therapy with lutetium-177 dotatate provides one of the clearest clinical benchmarks for biomarker-selected radiopharmaceutical deployment in solid tumors. In the pivotal randomized phase III NETTER-1 trial, patients with progressive, somatostatin receptor-positive advanced midgut neuroendocrine tumors treated with lutetium-177 dotatate combined with long-acting octreotide experienced markedly prolonged progression-free survival and higher objective response rates than those receiving high-dose octreotide alone. The final overall survival analysis revealed a numerical survival benefit that did not reach statistical significance, a result likely influenced by patient crossover and subsequent antineoplastic therapies. Clinical adoption has been codified through multidisciplinary procedural guidelines from organizations including the International Atomic Energy Agency, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the North American Neuroendocrine Tumor Society. These professional frameworks emphasize careful patient selection using somatostatin receptor imaging, renal tubular protection using co-infused amino-acid solutions, longitudinal marrow surveillance, and rigorous radiation-safety precautions.

Evidence for peptide receptor radionuclide therapy is actively expanding into earlier clinical lines and novel radiopharmaceutical designs. The randomized NETTER-2 trial demonstrated that first-line administration of lutetium-177 dotatate with octreotide LAR significantly improved progression-free survival in patients presenting with advanced grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors, extending systemic radioligand therapy beyond later-line settings. In parallel, the randomized COMPETE trial evaluated lutetium-177 edotreotide against the targeted molecular agent everolimus in progressive somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, testing radiopharmaceutical performance against an active systemic comparator. Early-phase studies are also investigating targeted alpha-emitter constructs, such as lead-212 DOTAMTATE, to determine whether high-linear-energy-transfer alpha emissions can overcome refractory disease in patients previously treated with beta-emitting radiopharmaceuticals. Despite these advances, clinical management faces persistent challenges, including non-standardized criteria for retreatment, long-term bone marrow risks, proximal tubular kidney exposure, and interlesional heterogeneity across diverse metastatic sites.

In metastatic castration-resistant prostate cancer, prostate-specific membrane antigen-targeted radioligand therapy represents a rapidly advancing treatment class. In the randomized phase III VISION trial, adding lutetium-177 PSMA-617 to protocol-permitted standard care significantly prolonged radiographic progression-free survival and overall survival in patients previously treated with androgen-receptor pathway inhibitors and taxane chemotherapy, while simultaneously delaying the worsening of pain and health-related quality of life. Complementary evidence from the randomized phase II TheraP trial compared lutetium-177 PSMA-617 directly with cabazitaxel in patients selected through dual-tracer imaging with both PSMA and fluorodeoxyglucose positron emission tomography. In that study, lutetium-177 PSMA-617 achieved higher prostate-specific antigen response rates and lower incidences of grade 3 or 4 adverse events, though mature follow-up demonstrated broadly similar overall survival between both treatment arms. Earlier application in taxane-naive disease has been demonstrated in the PSMAfore trial, which reported improved radiographic progression-free survival compared to an androgen-receptor pathway inhibitor switch.

Locoregional and orphan disease indications offer additional critical insights into the necessity of disciplined dosimetric workflows. In liver-dominant malignancies, yttrium-90 microsphere radioembolization delivers beta radiation through hepatic arterial branches. The prospective randomized DOSISPHERE-01 trial in hepatocellular carcinoma demonstrated that personalized glass-microsphere dosimetry significantly improved objective tumor response compared with standard fixed-activity planning, validating absorbed-dose optimization as a primary determinant of therapeutic outcome. For rare neuroendocrine tumors such as pheochromocytoma and paraganglioma, high-specific-activity iodine-131 MIBG targets the norepinephrine transporter system, relying on scan-positive avidity for therapeutic eligibility. Pediatric oncology protocols similarly combine iodine-131 MIBG with radiosensitizing chemotherapeutic agents such as topotecan to treat high-risk neuroblastoma. Because these clinical conditions are exceedingly rare, evidence bases frequently rely on single-arm cohorts and retrospective studies, yet they demonstrate how personalized internal radiation physics can directly influence clinical efficacy and normal-organ preservation.

The historical trajectory of radioimmunotherapy in B-cell lymphoma presents cautionary lessons regarding health-system integration. Monoclonal antibody conjugates such as yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab achieved regulatory approval by demonstrating clear clinical efficacy and improving progression-free survival in follicular lymphoma. However, both agents experienced limited clinical utilization, and iodine-131 tositumomab was ultimately withdrawn from commercial distribution. This outcome stemmed from logistical friction, complex radiation-safety requirements, prolonged antibody clearance that elevated marrow exposure, misaligned physician referral patterns, and competing oral or non-radioactive systemic therapies. Contemporary solid-tumor radioimmunotherapy development is therefore turning toward bioengineered antibody fragments, nanobodies, minibodies, and pretargeted delivery systems designed to accelerate systemic clearance and optimize tumor-to-background dose ratios. Experimental programs evaluating Trop-2-directed radioimmunotherapy in preclinical pancreatic cancer models illustrate this modern strategy, coupling precise tumor targeting with refined vector kinetics to circumvent the translational pitfalls encountered by earlier full-length antibody platforms.

Radiopharmaceutical researchers are now expanding their focus beyond prostate-specific membrane antigen and somatostatin receptors to target stromal, chemokine, and lineage-associated surface molecules. Fibroblast activation protein represents a major target because it is expressed by cancer-associated fibroblasts across numerous epithelial tumors, conceptually turning the surrounding tumor microenvironment into a therapeutic address. The chemokine receptor CXCR4 presents another mechanism-driven theranostic pathway relevant to hematologic malignancies and aggressive dissemination, although physiological expression within normal hematopoietic compartments creates distinct bone marrow toxicity boundaries. Other targets entering translational pipelines include B7-H4, carbonic anhydrase IX, gastrin-releasing peptide receptor, delta-like ligand 3, epidermal growth factor receptor, carcinoembryonic antigen, CD45, and human epidermal growth factor receptor 2. Preclinical testing of targeted alpha therapies, such as actinium-225-labeled Macropa-PEG4-FPA150 against B7-H4-positive solid tumors, highlights how newly identified surface antigens are being coupled with high-potency radionuclides to target treatment-resistant malignancies.

The physical properties of radionuclides are also diversifying beyond conventional beta emitters. However, alpha-emitter implementation remains complicated by salivary toxicity, daughter nuclide recoil and redistribution, microdosimetric estimation challenges, and restricted global supply. Emerging radiometals like terbium-161 provide combined beta emissions alongside short-range Auger and conversion electrons, creating concentrated microscopic energy deposition. The production of no-carrier-added terbium-161 requires thermal neutron irradiation of enriched gadolinium-160 targets followed by specialized radiochemical separation to isolate terbium from bulk gadolinium material. Matched theranostic element pairs, such as lead-203 for diagnostic imaging and lead-212 for alpha therapy, further illustrate the field’s deliberate efforts to ensure diagnostic imaging accurately reflects therapeutic biodistribution and organ dosimetry.

Establishing radiopharmaceutical therapy as a fully realized branch of precision radiation oncology requires closing major gaps in dosimetry, combination biology, and delivery infrastructure. Standard external-beam linear-quadratic radiobiology models cannot be directly applied to continuous, heterogeneous, low-dose-rate internal radiation without accounting for repair half-times and microdistribution. Rational combinations with DNA damage response inhibitors—such as PARP, ATR, ATM, and DNA-PK inhibitors—and radiosensitizing agents like capecitabine aim to enhance tumor radiosensitivity, yet they require cautious monitoring to avoid exacerbating bone marrow and gastrointestinal toxicities. Furthermore, widespread patient access is constrained by centralized manufacturing requirements, isotope production reactor capacities, and geographic disparities in specialized nuclear medicine facilities. The authors conclude that transforming radiopharmaceuticals into a durable systemic modality requires embedding prospective, adaptive dosimetry into multicenter trials, engineering scalable supply networks, and deploying rigorous multidisciplinary care teams across global oncology centers.

Subject of Research: Advances, biological complexities, and clinical implementation of precision oncology radiopharmaceutical therapies

Article Title: Radiopharmaceutical therapy in cancer: clinical momentum, biological complexity, and the next era of precision systemic radiation oncology

Article References: Ahire, V., & Dai, Y.-H. (2026). Radiopharmaceutical therapy in cancer: clinical momentum, biological complexity, and the next era of precision systemic radiation oncology. Frontiers in Nuclear Medicine, 6, Article 1997379. https://doi.org/10.3389/fnume.2026.1997379

Image Credits: AI Generated

DOI: 10.3389/fnume.2026.1997379

Keywords: radiopharmaceutical therapy, precision oncology, nuclear medicine, theranostics, targeted radionuclide therapy, internal dosimetry, prostate cancer, neuroendocrine tumors, Radiopharmaceutical, therapy, cancer, clinical